HPHA.XETRA

Heidelberg Pharma AG

HPHA.XETRA, Germany

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, the United States, and internationally. Its lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company develops HDP-102, an antibody and the compound Amanitin, which has completed preclinical development for the treatment of non-Hodgkin lymphoma; HDP-103, a proprietary ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors; HDP-201 for the treatment of colorectal cancer; and TAK-ATAC for the treatment of oncology. It also develops TLX250-CDx, a diagnostic antibody for kidney cancer that is in Phase III trials, as well as for the treatment of bladder cancer. In addition, the company develops TLX250 (girentuximab), a therapeutic antibody, which is in Phase II study for the treatment of kidney cancer; and RHB-107, an orally serine protease inhibitor that is in Phase II study to treat COVID-19. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is headquartered in Ladenburg, Germany.

https://heidelberg-pharma.com

Stock Price

€0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A

Analyst Ratings & Sentiment

(Last Updated 2025-08-31)

Rating:

STRONG BUY

$

Analyst Picks

Strong Buy

1

Buy

1

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-08-31)

Health Score

Price to Book Ratio (P/B)

-

Very High

13.48

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-80.37 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-15.66 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-22,916.11 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

4.13

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Heidelberg Pharma AG

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-11-30

EPS Estimate

0

Latest Release

Date

2025-08-31

EPS Actual

-0.18

EPS Estimate

0

EPS Difference

-0.18

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-08-31)

Deep Value
Weak Deep Value(2)
Defensive
Moderately Defensive(5)
Dividend
Weak Dividend Profile(1)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(1)
Value
Overpriced(1.5)

Income Statement

(Last Updated 2025-08-31)

Revenue

€ 0

Cost Of Revenue

€ 0

Gross Profit

€ 0

Operating Expenses

€ 0

Operating Income

€ 0

Interest Expense

€ 0

Pretax Income

€ 0

Net Income

€ 0

Income Tax Expense

€ 0

EBITDA

€ 0

Total Other Income Expense Net

€ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-08-31)

Cash

€ 0

Short Term Investments

€ 0

Receivables

€ 0

Inventories

€ 0

Total Current Assets

€ 0

Property Plant Equipment

€ 0

Total Assets

€ 0

Payables

€ 0

Short Term Debt

€ 0

Long Term Debt

€ 0

Total Liabilities

€ 0

Equity

€ 0

Trend

Cash Flow

(Last Updated 2025-08-31)

Net Income

€ 0

Depreciation

€ 0

Change In Working Capital

€ 0

Cash From Operations

€ 0

Capital Expenditures

€ 0

Cash From Investing

€ 0

Cash From Financing

€ 0

Net Change In Cash

€ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.